| Cash Flow | 2025-06-30 |
|---|---|
| Stock-based compensation expense | 559 |
| Net loss | -8,877 |
| Fair value of common stock issued for services | 0 |
| Non-cash interest expense on promissory note | 100 |
| Prepaid expenses and other current assets | -98 |
| Other liabilities | 646 |
| Operating lease liabilities, net | -67 |
| Deposits and other | -64 |
| Contract liability | -508 |
| Accrued expenses | -127 |
| Accounts receivable | 269 |
| Accounts payable | 608 |
| Depreciation and amortization | 483 |
| Fair value of warrants issued for services | 0 |
| Net cash used in operating activities | -7,290 |
| Acquisitions of property and equipment | 893 |
| Payment for acquisition, net of cash acquired of 865 | 5,135 |
| Net cash (used in) provided by investing activities | -6,028 |
| Proceeds from issuance of warrants | 1,699 |
| Proceeds from issuance of debt | 9,642 |
| Proceeds from issuance of common stock | 347 |
| Payments for issuance costs | 837 |
| Proceeds from issuance of pre-funded warrants | 609 |
| Net cash provided by financing activities | 11,460 |
| Net (decrease) increase in cash and cash equivalents | -1,858 |
Vivos Therapeutics, Inc. (VVOS)
Vivos Therapeutics, Inc. (VVOS)